Patents by Inventor Veena KRISHNAMOORTHY

Veena KRISHNAMOORTHY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR CULTURING CELLS EXPRESSING C-JUN
    Publication number: 20230313138
    Abstract: Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to overexpress c-Jun and/or comprise one or more exogenous nucleotide sequences encoding a ligand binding protein. In some aspects, the immune cells are administered to a subject in need thereof.
    Type: Application
    Filed: October 27, 2022
    Publication date: October 5, 2023
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Suman Kumar VODNALA, Veena KRISHNAMOORTHY, Spencer PARK, Queenie VONG, Blythe SATHER
  • METHODS FOR CULTURING CELLS EXPRESSING ROR1-BINDING PROTEIN
    Publication number: 20230310605
    Abstract: Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to express a ROR1-binding protein and have increased level of c-Jun protein. In some aspects, the immune cells are administered to a subject in need thereof.
    Type: Application
    Filed: October 27, 2022
    Publication date: October 5, 2023
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Suman Kumar VODNALA, Veena KRISHNAMOORTHY, Spencer PARK, Queenie VONG, Blythe SATHER
  • ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
    Publication number: 20230059489
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: June 24, 2022
    Publication date: February 23, 2023
    Inventors: Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER
  • Antibodies specific for FLT3 and their uses
    Patent number: 11421040
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 23, 2022
    Assignee: Pfizer Inc.
    Inventors: Danielle Elizabeth Dettling, Yik Andy Yeung, Kristian Todd Poulsen, Veena Krishnamoorthy, Cesar Adolfo Sommer
  • ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
    Publication number: 20180346601
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Applicant: PFIZER INC.
    Inventors: Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER